87 related articles for article (PubMed ID: 9885378)
1. Increased serum concentration of circulating soluble receptor for interleukin-2 and its effect as a prognostic indicator in cachectic patients with gastric and colorectal cancer.
Shibata M; Takekawa M
Oncology; 1999; 56(1):54-8. PubMed ID: 9885378
[TBL] [Abstract][Full Text] [Related]
2. Increased serum concentrations of soluble tumor necrosis factor receptor I in noncachectic and cachectic patients with advanced gastric and colorectal cancer.
Shibata M; Takekawa M; Amano S
Surg Today; 1998; 28(9):884-8. PubMed ID: 9744395
[TBL] [Abstract][Full Text] [Related]
3. Serum level of a soluble receptor for interleukin-2 as a prognostic factor in patients with gastric cancer.
Saito H; Tsujitani S; Ikeguchi M; Maeta M; Kaibara N
Oncology; 1999 Apr; 56(3):253-8. PubMed ID: 10202282
[TBL] [Abstract][Full Text] [Related]
4. Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.
Nakata B; Chung KH; Kato Y; Yamashita Y; Inui A; Arimoto Y; Maeda K; Onoda N; Sawada T; Sowa M
Br J Cancer; 1998 Jun; 77(11):1820-4. PubMed ID: 9667652
[TBL] [Abstract][Full Text] [Related]
5. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer.
Berghella AM; Pellegrini P; Del Beato T; Adorno D; Casciani CU
Cancer Biother Radiopharm; 1997 Aug; 12(4):265-72. PubMed ID: 10851474
[TBL] [Abstract][Full Text] [Related]
6. Levels of serum-soluble receptor for interleukin-2 in patients with colorectal cancer.
Saito H; Tsujitani S; Katano K; Ikeguchi M; Maeta M; Kaibara N
Surg Today; 1998; 28(10):1115-7. PubMed ID: 9786595
[TBL] [Abstract][Full Text] [Related]
7. Circulating levels of soluble CD30 and other markers in colorectal cancer patients.
Iwagaki H; Hizuta A; Kohka H; Kobashi K; Nitta Y; Isozaki H; Takakura N; Tanaka N
J Med; 1999; 30(1-2):111-21. PubMed ID: 10515247
[TBL] [Abstract][Full Text] [Related]
8. Serum concentrations of neopterin, soluble interleukin 2 receptor, and soluble tumor necrosis factor receptor in Wegener's granulomatosis.
Nassonov EL; Samsonov MY; Tilz GP; Beketova TV; Semenkova EN; Baranov A; Wachter H; Fuchs D
J Rheumatol; 1997 Apr; 24(4):666-70. PubMed ID: 9101499
[TBL] [Abstract][Full Text] [Related]
9. Serum Soluble Interleukin-2 Receptor is Increased in Malnourished and Immunosuppressed Patients With Gastric and Colorectal Cancer: Possible Influence of Myeloid-Derived Suppressor Cells.
Gonda K; Shibata M; Shimura T; Machida T; Suzuki S; Nakamura I; Ohki S; Sakurai K; Ohto H; Tomita R; Takenoshita S
World J Oncol; 2012 Aug; 3(4):158-164. PubMed ID: 29147299
[TBL] [Abstract][Full Text] [Related]
10. Circulating ghrelin in patients with gastric or colorectal cancer.
Huang Q; Fan YZ; Ge BJ; Zhu Q; Tu ZY
Dig Dis Sci; 2007 Mar; 52(3):803-9. PubMed ID: 17245626
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Malagnino G; Prontera C; Fanucchi A; Annicchiarico C; Bianchi R; Fioretti P; Facchini V
Gynecol Oncol; 1994 Mar; 52(3):386-91. PubMed ID: 8157196
[TBL] [Abstract][Full Text] [Related]
12. [The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients].
Siemińska A
Pol Merkur Lekarski; 2004 Feb; 16(92):188-90. PubMed ID: 15176308
[TBL] [Abstract][Full Text] [Related]
13. The clinical significance of serum soluble interleukin 2 receptor (sIL-2R) concentration in lung cancer.
Naumnik W; Chyczewska E
Folia Histochem Cytobiol; 2001; 39 Suppl 2():185-6. PubMed ID: 11820599
[TBL] [Abstract][Full Text] [Related]
14. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers.
Ziegenhagen MW; Benner UK; Zissel G; Zabel P; Schlaak M; Müller-Quernheim J
Am J Respir Crit Care Med; 1997 Nov; 156(5):1586-92. PubMed ID: 9372680
[TBL] [Abstract][Full Text] [Related]
15. Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.
Goto H; Tsurumi H; Takemura M; Ino-Shimomura Y; Kasahara S; Sawada M; Yamada T; Hara T; Fukuno K; Goto N; Okuno M; Takami T; Seishima M; Moriwaki H
J Cancer Res Clin Oncol; 2005 Feb; 131(2):73-9. PubMed ID: 15503137
[TBL] [Abstract][Full Text] [Related]
16. Serum soluble interleukin-2 receptor (IL-2R) and immunohistochemical staining of IL-2R/Tac antigen in colorectal cancer.
Sakata H; Murakami S; Hirayama R
Int J Clin Oncol; 2002 Oct; 7(5):312-7. PubMed ID: 12402066
[TBL] [Abstract][Full Text] [Related]
17. Neopterin serum levels in pancreatic adenocarcinoma.
Manes G; Spada OA; Rabitti PG; Feola B; Misso S; Minerva A; Uomo G
Int J Pancreatol; 1999 Feb; 25(1):31-7. PubMed ID: 10211419
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of serum biological markers in patients with hepatocellular carcinoma.
Parasole R; Izzo F; Perrone F; Pignata S; Galati MG; Leonardi E; Castiglione F; Orlando R; Castello G; Esposito G; Gallo C; Daniele B
Clin Cancer Res; 2001 Nov; 7(11):3504-9. PubMed ID: 11705869
[TBL] [Abstract][Full Text] [Related]
19. Prognostic relevance of soluble interleukin-2 receptors in patients with ovarian tumors.
Gebauer G; Rieger M; Jäger W; Lang N
Anticancer Res; 1999; 19(4A):2509-11. PubMed ID: 10470184
[TBL] [Abstract][Full Text] [Related]
20. Serum soluble interleukin-2 receptor (sIL-2R) level is associated with the outcome of patients with diffuse large B cell lymphoma treated with R-CHOP regimens.
Goto N; Tsurumi H; Goto H; Shimomura YI; Kasahara S; Hara T; Yasuda I; Shimizu M; Murakami N; Yoshikawa T; Fukuno K; Takahashi T; Kito Y; Takami T; Moriwaki H
Ann Hematol; 2012 May; 91(5):705-714. PubMed ID: 22183251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
